We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$1.39B
Cap. Flow %
-6.39%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Communication Services 8.41%
3 Technology 5.7%
4 Financials 3.99%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRFS
126
Grifois
GRFS
$5.44B
– –
-28,000
Closed -$225K
GTX icon
127
Garrett Motion
GTX
$4.96B
– –
-275,000
Closed -$5M
H icon
128
Hyatt Hotels
H
$17B
– –
-36,000
Closed -$5.18M
HIMS icon
129
Hims & Hers Health
HIMS
$7.88B
– –
-10,000
Closed -$208K
HQY icon
130
HealthEquity
HQY
$8.81B
– –
-2,800
Closed -$234K
HR icon
131
Healthcare Realty
HR
$6.65B
– –
-12,000
Closed -$204K
INTR icon
132
Inter&Co
INTR
$2.38B
– –
-614,500
Closed -$4.89M
IONS icon
133
Ionis Pharmaceuticals
IONS
$9.93B
– –
-4,800
Closed -$360K
IOVA icon
134
Iovance Biotherapeutics
IOVA
$3.76B
– –
-26,000
Closed -$91.3K
IRWD icon
135
Ironwood Pharmaceuticals
IRWD
$709M
– –
-13,000
Closed -$45.6K
KRYS icon
136
Krystal Biotech
KRYS
$10.3B
– –
-1,000
Closed -$258K
LFUS icon
137
Littelfuse
LFUS
$10.5B
– –
-15,000
Closed -$5.09M
LIVN icon
138
LivaNova
LIVN
$4.34B
– –
-6,000
Closed -$381K
MA icon
139
Mastercard
MA
$509B
– –
-435,071
Closed -$217M
MCK icon
140
McKesson
MCK
$100B
– –
-234,300
Closed -$203M
MDGL icon
141
Madrigal Pharmaceuticals
MDGL
$11.9B
– –
-3,319
Closed -$1.74M
MIRM icon
142
Mirum Pharmaceuticals
MIRM
$5.87B
– –
-3,000
Closed -$277K
MMSI icon
143
Merit Medical Systems
MMSI
$5.42B
– –
-3,000
Closed -$207K
MOH icon
144
Molina Healthcare
MOH
$10.5B
– –
-35,000
Closed -$4.67M
MTZ icon
145
MasTec
MTZ
$21.4B
– –
-17,000
Closed -$5.47M
NEO icon
146
NeoGenomics
NEO
$2.18B
– –
-19,000
Closed -$141K
NKTR icon
147
Nektar Therapeutics
NKTR
$2.53B
– –
-4,000
Closed -$288K
NOW icon
148
ServiceNow
NOW
$133B
– –
-41,000
Closed -$4.29M
NUVB icon
149
Nuvation Bio
NUVB
$2.43B
– –
-29,000
Closed -$124K
NUVL
150
DELISTED
Nuvalent
NUVL
– –
-3,000
Closed -$307K
4 5
6
7 8

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2026 Portfolio in Review

As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
  • Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.